GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (MEX:NVAX) » Definitions » Research & Development

Novavax (MEX:NVAX) Research & Development : MXN7,672 Mil (TTM As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is Novavax Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Novavax's Research & Development for the three months ended in Mar. 2025 was MXN1,819 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was MXN7,672 Mil.

Novavax Research & Development Historical Data

The historical data trend for Novavax's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novavax Research & Development Chart

Novavax Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14,859.86 51,992.90 24,082.98 12,518.54 8,158.10

Novavax Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,538.12 1,959.26 1,716.29 2,176.92 1,819.49

Novavax Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN7,672 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax  (MEX:NVAX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Novavax Research & Development Related Terms

Thank you for viewing the detailed overview of Novavax's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Novavax Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novavax Inc (MEX:NVAX) » Definitions » Research & Development
Comparable Companies
VRDN WVE AUPH MDXG ETNB INVA SNDX IOVA XFOR ADPT VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
NVAX:USA NVV1:Germany NVV1:Germany NVV1:Germany NVV1:Bulgaria NVAX:Austria
Address
700 Quince Orchard Road, Gaithersburg, MD, USA, 20878
Website
https://www.novavax.com
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.